Article info

Download PDFPDF

312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
Free

Authors

Citation

Moore K, Redhead K, Goble S, et al
312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

Publication history

  • First published September 18, 2019.
Online issue publication 
September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.